Farther Finance Advisors LLC Has $812,000 Stock Holdings in Sanofi $SNY

Farther Finance Advisors LLC raised its stake in Sanofi (NASDAQ:SNY) by 201.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,197 shares of the company’s stock after buying an additional 11,486 shares during the period. Farther Finance Advisors LLC’s holdings in Sanofi were worth $812,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Brighton Jones LLC boosted its holdings in shares of Sanofi by 52.6% during the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after acquiring an additional 1,869 shares in the last quarter. Ieq Capital LLC increased its holdings in Sanofi by 25.7% in the first quarter. Ieq Capital LLC now owns 11,963 shares of the company’s stock valued at $663,000 after purchasing an additional 2,443 shares during the period. Vident Advisory LLC lifted its holdings in Sanofi by 14.7% during the 1st quarter. Vident Advisory LLC now owns 15,560 shares of the company’s stock worth $863,000 after buying an additional 1,994 shares during the period. Baird Financial Group Inc. grew its position in shares of Sanofi by 14.8% in the 1st quarter. Baird Financial Group Inc. now owns 164,161 shares of the company’s stock valued at $9,104,000 after buying an additional 21,121 shares during the last quarter. Finally, Royal Bank of Canada increased its stake in shares of Sanofi by 1.7% in the first quarter. Royal Bank of Canada now owns 2,432,701 shares of the company’s stock valued at $134,916,000 after buying an additional 40,213 shares during the period. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SNY has been the topic of a number of recent analyst reports. HSBC reaffirmed a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a research note on Monday, December 22nd. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a research report on Monday, October 27th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $62.67.

Sanofi Stock Performance

Shares of SNY stock opened at $48.35 on Tuesday. The company has a market cap of $118.70 billion, a price-to-earnings ratio of 11.32, a price-to-earnings-growth ratio of 1.32 and a beta of 0.44. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12. The company has a quick ratio of 0.30, a current ratio of 1.06 and a debt-to-equity ratio of 0.16. The firm has a 50 day moving average of $49.62 and a 200-day moving average of $48.88.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 24th. The company reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $1.31. The company had revenue of $15.46 billion for the quarter, compared to the consensus estimate of $12.62 billion. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. Sanofi’s quarterly revenue was down 7.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.25 EPS. On average, equities analysts forecast that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.